Evidence map›Paper›PMID 25492703›Full record

ArticleScientific reports2014

Vector modifications to eliminate transposase expression following piggyBac-mediated transgenesis.

Syandan Chakraborty, HaYeun Ji, Jack Chen, Charles A Gersbach, Kam W Leong

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Accelerating Diverse Cell-Based Therapies Through Scalable Design.Annual review of chemical and biomolecular engineering · 2024
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Syandan ChakrabortyDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, 27708, USA.
HaYeun JiDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, 27708, USA.
Jack ChenDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, 27708, USA.
Charles A Gersbach1] Department of Biomedical Engineering, Duke University, Durham, North Carolina, 27708, USA [2] Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, 27708, USA [3] Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, 27708, USA.
Kam W LeongDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, 27708, USA.
Duke University · US

Funding

Engineering Morphogenetic Factors for Enhanced Genetic ReprogrammingDP2OD008586 · OD · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 2011 to 2011
$2.4M
Circulatory system and integrated muscle tissue for drug and tissue toxicityUH2TR000505 · NCATS · DUKE UNIVERSITY · PI TRUSKEY, GEORGE A · 2012 to 2013
$2.1M
Overcoming Immunosenescence by Nanoparticle-Mediated ActivationR01AI096305 · NIAID · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N, LEONG, KAM W · 2012 to 2016
$1.8M
Derivation of Functional Neurons from Human Adult Cells by Nonviral Gene DeliveryR21EB015300 · NIBIB · DUKE UNIVERSITY · PI LEONG, KAM W · 2012 to 2013
$421k
NCATS NIH HHS UH2 TR000505NCATS NIH HHS UH2TR000505NIAID NIH HHS AI096305NIAID NIH HHS R01 AI096305NIBIB NIH HHS EB015300NIBIB NIH HHS R21 EB015300NIH HHS DP2 OD008586NIH HHS DP2OD008586
6 · The paper itself

Abstract

Transgene insertion plays an important role in gene therapy and in biological studies. Transposon-based systems that integrate transgenes by transposase-catalyzed "cut-and-paste" mechanism have emerged as an attractive system for transgenesis. Hyperactive piggyBac transposon is particularly promising due to its ability to integrate large transgenes with high efficiency. However, prolonged expression of transposase can become a potential source of genotoxic effects due to uncontrolled transposition of the integrated transgene from one chromosomal locus to another. In this study we propose a vector design to decrease post-transposition expression of transposase and to eliminate the cells that have residual transposase expression. We design a single plasmid construct that combines the transposase and the transpositioning transgene element to share a single polyA sequence for termination. Consequently, the separation of the transposase element from the polyA sequence after transposition leads to its deactivation. We also co-express Herpes Simplex Virus thymidine kinase (HSV-tk) with the transposase. Therefore, cells having residual transposase expression can be eliminated by the administration of ganciclovir. We demonstrate the utility of this combination transposon system by integrating and expressing a model therapeutic gene, human coagulation Factor IX, in HEK293T cells.

Indexed as

DNA Transposable ElementsGene ExpressionGene Transfer TechniquesChromosomes, HumanFactor IXGenetic TherapyGenetic VectorsHEK293 CellsHumansThymidine KinaseTransposasesViral ProteinsDNA Transposable ElementsFactor IXThymidine KinaseTransposasesViral Proteins

Identifiers

PMID25492703
PMCPMC4261183
OpenAlexW2056025633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.